The mechanisms by which tobacco promotes lung cancer remain incompletely understood. Herein, we report that nicotine, a major component of tobacco, promotes the proliferation of cultured nonsmall cell lung carcinoma (NSCLC) cells; this effect was most noticeable at 5 days. However, nicotine had no effect on apoptosis of NSCLC cells. In experiments designed to unveil the mechanisms for this effect, we found that nicotine also stimulated mRNA and protein expression of fibronectin. Fibronectin is a matrix glycoprotein that regulates important cellular processes (e.g., adhesion, proliferation, and differentiation) and is highly expressed in tobacco-related lung disorders. Of note, reagents against the integrin a5b1 (antibodies, RGD peptides, a5 shRNA) blocked the mitogenic effects of nicotine. Thus, nicotine stimulated NSCLC cell proliferation indirectly via fibronectin induction. We then focused on the mechanisms responsible for nicotine-induced fibronectin expression in NSCLC cells and found that nicotine stimulated the surface expression of a7 nicotinic acetylcholine receptor (a7 nAChR), and that a-bungarotoxin, an inhibitor of a7 nAChR, abolished the nicotine-induced fibronectin response. The fibronectin-inducing effects of nicotine were associated with activation of extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3-K)/mammalian target of rapamycin (mTOR) signaling pathways, and were abrogated by inhibitors of ERK (PD98059), PI3-K (LY294002), and mTOR (rapamycin), but not by inhibitors of protein kinase (PK)C (calphostin C) and PKA (H89). These observations suggest that nicotine stimulates NSCLC proliferation through induction of fibronectin, and that these events are mediated through nAChR-mediated signals that include ERK and PI3-K/mTOR pathways. This work highlights the role of fibronectin and a5b1 integrins as potential targets for anti-lung cancer therapies.
Lung carcinoma is one of the most common malignant tumors in the world, and is the leading cause of carcinoma death in the United States. Despite recent advances in understanding the molecular biology of lung carcinoma and the introduction of multiple new chemotherapeutic agents for its treatment, its dismal 5-year survival rate (, 15%) has not changed substantially (1) . It is well known that tobacco use is the most important risk factor for the development of lung carcinoma in the United States. In particular, non-small cell lung cancer (NSCLC) demonstrates a strong etiologic association with smoking. Although nicotine, a major component of tobacco, is not carcinogenic by itself, it can induce cancer cell proliferation and angiogenesis, and suppress apoptosis induced by certain agents (2) . The mitogenic effects of nicotine were recently reported to be mediated via the a7 nicotinic acetylcholine receptor (a7 nAChR) (3) . In general, these studies were performed in serum-starved cells. Nevertheless, they suggest that nicotine may directly contribute to NSCLC progression.
One characteristic shared by tobacco-related and other chronic lung diseases is altered lung connective tissue content and composition. In particular, they are associated with increased expression and deposition in the lung of fibronectin. Fibronectin is a 250-kD heterodimeric extracellular matrix glycoprotein implicated in physiologic events during embryogenesis, angiogenesis, thrombosis, and inflammation (4) . Fibronectin is also expressed in several cancer cells, especially in NSCLC cell lines (5) , and the adhesion of lung carcinoma cells to fibronectin enhances tumorigenicity and confers resistance to apoptosis induced by standard chemotherapeutic agents (6) . Furthermore, fibronectin is believed to play a role in tumor growth (7, 8) . We previously showed that fibronectin stimulates NSCLC cell growth and reduces apoptosis through activation of the integrin a5b1, induction of cyclooxygenase-2 (COX-2), inhibition of cyclin-dependent kinase inhibitor p21Waf1/Cip1 gene expression, and stimulation of mammalian target of rapamycin (mTOR) signaling (9) (10) (11) . The above information suggests that fibronectin promotes lung tumor growth/survival and resistance to therapy, and could represent a novel target for the development of new anticancer drugs.
These earlier studies emphasized the potential role of fibronectin in tumor proliferation. We speculated that excessive deposition of fibronectin in lung in tobacco-related and chronic fibrotic lung disorders would render the host susceptible to rapid tumor proliferation in cases of oncogenic transformation (11, 12) . Here, we explore the role of tumor-derived fibronectin in this process as it relates to nicotinic stimulation. We report, for the first time, that nicotine binding to a7 nAChRs stimulates human lung carcinoma cell growth through activation of extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3-K)/mTOR signaling pathways that lead to fibronectin expression. Thus, tumor-derived fibronectin is an important mediator of nicotine-induced tumor cell proliferation.
CLINICAL RELEVANCE
This work unveils a novel role for fibronectin and matrixbinding integrins in tobacco-related lung carcinoma cell progression, and points to potential new targets for the development of adjuvant therapies in tobacco-related tumors.
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MATERIALS AND METHODS

Culture and Chemicals
The human NSCLC cell line H460 was obtained from the American Type Culture Collection (Manassas, VA), and was cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), HEPES buffer, 50 IU/ml penicillin/streptomycin, and 1 mg amphotericin (complete medium) as previously described (13) . Antibodies specific for a7 nAChR (H-302) and the a5 integrin subunit (H-104) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal antibodies for fibronectin and GAPDH were obtained from Abcam Inc. (Cambridge, UK), and antibodies against Akt, phosphorylated active Akt (p-Akt, Thr 307), mTOR, p-mTOR (Ser2481), ERK1/2, p-ERK1/2 (T202/Y204), the mitogen-activated protein kinase (MAPK)-specific inhibitor PD98059, and the FRAP/mTOR inhibitor rapamycin, were purchased from Cell Signaling (Beverly, MA). The mouse monoclonal anti-human a5b1 integrin (JBS5) and anti-human a2b1 integrin (AB1944) antibodies were purchased from Chemicon International, Inc. (Temecula, CA). The PI3-K inhibitor LY294002, the a7 nAChR antagonist a-bungarotoxin, the protein kinase A (PKA) inhibitor H-89, and the protein kinase C (PKC) inhibitor Calphostin C were obtained from Calbiochem (San Diego, CA). The LightCycler/FastStart DNA Master SYBER Green I kit was purchased from Roche Molecular Biochemicals (Indianapolis, IN). All RT-PCR kit components were obtained from Perkin Elmer Co. (Foster City, CA). The CellTiter-Glo Luminescent Cell Viability Assay Kit and the Caspase-Glo 3/7 Assay Kit were purchased from Promega Co. (Madison, WI). The GRGDdSP and GRGESP peptides were obtained from Life Technologies, Inc. (Gaithersburg, MD). The monoclonal anticellular fibronectin antibody (Clone FN-3E2) and all other chemicals were purchased from Sigma (St. Louis, MO) unless otherwise indicated.
Cell Viability Assay and Caspase 3/7 Activity Detection H460 cells were plated at the indicated densities (2310 3 cells/well) in 96-well multiwell culture plates (Costar). Nicotine (0-10 23 M), antia5b1 and anti-a2b1 integrin antibodies (25 mg/ml each), and GRGDdSP or GRGESP peptides (2.5 mM each) were added to the culture medium (containing 10% FBS) after cell adherence. Treatments were repeated every 2 days. The CellTiter-Glo Luminescent Cell Viability Assay is a homogenous method of determining the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. The Caspase-Glo 3/7 Assay is a homogeneous, luminescent assay that measures caspase-3 and -7 activities, which play key effector roles in apoptosis in mammalian cells. Before luminescence recording, samples were incubated at room temperature for approximately 30 minutes followed by the addition of CellTiter-Glo reagent for 10 minutes or Caspase-Glo 3/7 reagent for 1 hour of incubation at room temperature. The luminescence signal was recorded on an Ascent luminometer (Thermo Labsystems, Helsinki, Finland) according to the manufacturer's protocols.
RT-PCR
Total RNA was prepared from H460 cells treated with nicotine in the presence or absence of a-bungarotoxin using the TRIzol Reagent (GIBCO BRL, Rockville, MD) according to the manufacturer's instructions. To amplify the a7 nAChR (397 bp), fibronectin (203 bp), and GAPDH (200 bp) cDNA fragments, the sequences of PCR primers (Sigma Genosys, Woodlands, TX) were as follows. For human a7 nAChR-forward primer: 59-GCTTTGACGCCACATTCC-39, reverse primer: (59-TGCAGGAAGCAGGAACAC-39); for human fibronectin-forward primer: 59-CCGTGGGCAACTCTGTC-39, reverse primer: 59-TGCGGCAGTTGTCACAG-39; and for GAPDHforward primer: 59-CCATGGAGAAGGCTGGGG-39, reverse primer: 59-CAAAGTTGTCATGGATGACC-39, according to published data (14) . The RT-PCR was carried out as previously described (15) . The samples were first denatured at 958C for 15 minutes, followed by 42 PCR cycles, each with temperature variations as follows: 958C for 15 seconds, 568C for 30 seconds, and 728C for 60 seconds. For a7 nAChR amplification, the annealing temperature was 668C. The last cycle was followed by an additional extension incubation of 7 minutes at 728C. Analysis of amplicons was accomplished on 1% agarose gel containing 0.2 mg/ml ethidium bromide, visualized under an ultraviolet transiluminator, and quantified using a Bio-Rad GS 800 Laser Densitometer (Hercules, CA).
Real-Time RT-PCR
This procedure is based on the time point during cycling when amplification of the PCR product is first detected, rather than on the amount of PCR product accumulated after a fixed number (16) . Final results were expressed as n-fold difference in a7 nAChR or fibronectin mRNA expression relative to the GAPDH gene. All PCR reactions using LightCycler-FastStart DNA Master SYBR Green I kit were performed in the Cepheid Smart-Cycler real-time PCR cycler (Sunnyvale, CA). Experiments were performed in triplicate for each data point.
Western Blot Analysis
The procedure was performed as previously described (17) . Briefly, the cultured cells were washed and lysed in 0.05 to 0.2 ml of cell extraction buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na 2 P 2 O 7 , 2 mM Na 3 VO 4 , 1% Triton X-100, 10% glycerol, 0.1%SDS, 0.5% deoxycholate, 1 mM PMSF, and protease inhibitor cocktail), then sonicated for 10 seconds. Protein concentrations were determined by the Bio-Rad protein assay. Equal amounts of protein (5-30 mg) from whole cell lysates were solubilized in 23 SDS-sample buffer and separated on SDS-polyacrylamide gels. The separated proteins were transferred onto nitrocellulose and blocked with Blotto with 5% bovine serum albumin or 5% nonfat dry milk and 0.1% Tween 20 for 1 hour at room temperature, and washed three times for 10 minutes with wash buffer (13 TBST). Blots were incubated with primary antibodies raised against p-Akt (1:500), cellular fibronectin (1:400), fibronectin (1:8,000), a5 integrin, a7 nAChR, p-mTOR, p-ERK1/2, Akt, mTOR or ERK1/2 (1:1,000) overnight at 48C, washed with wash buffer, and incubated with a secondary antibody raised against rabbit IgG conjugated to horseradish peroxidase (1:2,000 dilution; Cell Signaling) or peroxidase-conjugated donkey anti-mouse IgG (1:20,000 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 hour at room temperature. The blots were washed, transferred to freshly made ECL solution (Amersham, Arlington, IL) and exposed to X-ray film. Protein bands were quantified by densitometer scanning using a BioRad GS-800 calibrated densitometer. In controls, the specific antibodies were omitted or replaced by serum IgG.
Electroporation Transfection of Control and a5 shRNA Vectors
Electroporation was used to introduce the integrin a5 shRNA plasmid DNA (NM_010577; Sigma Aldrich, St. Louis, MO) or control shRNA vector (SHCOO2) into H460 cells. Briefly, cells were washed and resuspended in electroporation media (20 mM Hepes, 137 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 , 6 mM Dextrose, pH 7.05). H460 cells (2.3 3 10 7 cells) were added to electroporation cuvettes (0.4 cm electrode gap) along with 160 mg of integrin a5 shRNA plasmid DNA and subjected to 390 v and 500 mF (Gene Pulser II Electroporation System; Bio-Rad). Electroporated cells were pooled, aliquoted into tissue culture plates, and incubated at 378C and 5% CO 2 . Electroporated cells (2.5 3 10 5 cells per well) were added to 6-well tissue culture plates, incubated for 48 hours at 378C and 5% CO 2 , and subjected to Western blot analysis for the integrin a5. Also, electroporated cells (1 3 10 4 cells per well) were added to 48-well tissue culture plates, incubated with 10 24 M nicotine for 5 days at 378C and 5% CO 2 , and subjected to cell viability analysis (Promega).
Statistical Analysis
All experiments were repeated a minimum of three times. All data collected from Western blot, RT-PCR, real-time RT-PCR, and cell proliferation and caspase 3/7 activity assays were expressed as means 6 SD. The data presented in some figures are from a representative experiment, which was quantitatively similar in the replicate experiments. Statistical significance was determined with Student's t test (two-tailed) comparison between two groups of data set. Asterisks shown in the figures indicate significant differences of experimental groups compared with the corresponding control condition (P , 0.05, see figure legends).
RESULTS
Nicotine Stimulates NSCLC Cell Proliferation, but Has No Effect on Cell Apoptosis
Nicotine was recently reported to stimulate NSCLC cell proliferation within 18 hours of stimulation (3) . However, these studies were performed in cells starved from serum for 48 hours. To examine the effects of nicotine in more physiologic conditions, we tested cells cultured in the presence of 10% FBS. Under such conditions, the effects of nicotine were less dramatic and retarded ( Figures 1A and 1B) . A noticeable increase in cell number was observed in nicotine-treated cultures after a 4-to 5-day exposure period ( Figure 1B ). As depicted in Figure  1A , the nicotine effect was dose dependent, with significant induction at concentrations from 10 28 to 10 24 M. The most robust and consistent effect (more than 50% increase of control) was seen with 10 24 M. Higher doses (10 23 M) decreased cell growth, possibly due to cytotoxicity. In order to examine if the effect of nicotine on cell growth is due to a reduction in cell apoptosis, we examined for caspase 3/7 activity. As shown in Figure 1C , we found no significant difference between groups with respect to caspase 3/7 activity.
Nicotine Increases Fibronectin Gene Expression in NSCLC
Because of data implicating fibronectin in NSCLC proliferation, we explored the role of this glycoprotein. We began by evaluating the effect of nicotine on fibronectin expression in the cell extracts of NSCLC cells. As shown in Figures 2A and 2B , RT-PCR analysis revealed a time-and dose-dependent nicotine induction of fibronectin mRNA with a maximal increase after 48 hours of culture in the presence of 10 27 M nicotine. This was confirmed by real-time RT-PCR ( Figure 2C ), which indicated that nicotine increased fibronectin mRNA expression by 2.63-fold compared with its control value. Note that high doses of nicotine decreased fibronectin expression in NSCLC cells. In accordance with the changes observed in fibronectin mRNA, intracellular fibronectin protein was increased in nicotinetreated cells in a dose-dependent fashion, with an almost 3-fold increase compared to the control value at 10 27 M ( Figure 2D ). The stimulatory effect of nicotine on fibronectin protein expression in NSCLC cells was maximal at 48 hours and reduced at 72 hours ( Figure 2E ). We speculated that the fibronectin secreted in response to nicotine stimulated cell proliferation. Consistent with this idea, we detected an increase in fibronectin secreted into the medium with higher levels found at 4 and 5 days of nicotine treatment; this coincided with the time of maximal stimulation of proliferation ( Figure 2F ).
Integrin a5b1 Receptor Antibodies, GRGDdSP Peptide, and a5 shRNA Block the Effect of Nicotine on Cell Growth
The above findings suggested that nicotine-induced tumor cell proliferation was related to increased fibronectin expression. Thus, we set out to test the role of fibronectin in this process.
To this end, we tested the effects of agents capable of inhibiting the function of a5b1 integrin fibronectin receptors, thereby blocking fibronectin recognition by tumor cells. As shown in Figures 3A and 3B , nicotine-induced cell proliferation was blocked by an anti-a5b1 antibody as well as by the hexapeptide GRGDdSP, which competitively inhibits fibronectin binding to the integrin. The a2b1 antibody, an anti-collagen/lamininbinding integrin, and the control hexapeptide GRGESP, had no effect. A third strategy used involved the silencing of a5b1 receptors via shRNA knockdown ( Figures 3C and 3D ). Note that treatment with the a5 shRNA inhibited a5 expression ( Figure 3C ), while it had no effect on the collagen-binding integrin a2b1 (not shown). This intervention also abolished nicotineinduced cell proliferation ( Figures 3C and 3D) . These results strongly suggest that nicotine-stimulated NSCLC cell proliferation involves a5b1-mediated signals activated by fibronectin.
Nicotine Increases Expression of a7 nAChR and an Inhibitor of a7 nAChR Blocks Nicotine-Induced Fibronectin Expression
Having established a role for fibronectin-a5b1 binding in the nicotine-induced response, we set out to investigate the mechanisms responsible for fibronectin expression. We speculated that nicotine induced fibronectin expression by activating a7 nAChRs. We and others have reported nicotine induction of a7 nAChR expression in several cell types (2, 12) . A similar effect was also found in H460 cells in this study. Nicotine increased a7 nAChR protein levels in a dose-dependent manner, with Afterward, the luminescence of viable cells was detected using Cell Titer-Glo Luminescent Cell Viability Assay Kit according to the protocol of the manufacturer. (C) Nicotine does not affect caspase activity in NSCLC. H460 cells were treated with 10 24 M nicotine for 5 days or left untreated. Afterward, the luminescence of caspase 3/7 activity was detected using the Caspase-Glo 3/7 Assay Kit according to the manufacturer's instructions (Promega). All data are depicted as mean 6 SD. *Significant difference from untreated control condition (P , 0.05). a significant increase observed at 10 27 M at 24 hours ( Figure  4A ). This was associated with increased a7 nAChR mRNA expression as evidenced by RT-PCR and real-time RT-PCR ( Figures 4B and 4C) . To verify whether nicotine-induced fibronectin expression was mediated through a7 nAChR, abungarotoxin, an inhibitor of a7 nAChR, was used. We found that a-bungarotoxin, used at doses previously shown to be noncytotoxic (18) , abrogated the effect of nicotine on fibronectin mRNA and protein expression (Figures 4D and 4E) .
Involvement of ERK, Akt, and mTOR in Induction of Fibronectin Expression by Nicotine
We then tested whether regulation of fibronectin expression by nicotine was mediated by ERK and PI3-K/mTOR kinase was isolated from H460 cells treated with increasing concentrations of nicotine for 48 hours followed by Western blot analysis for fibronectin protein using an anti-fibronectin antibody. Blots were also incubated with an anti-GAPDH antibody to control for gel loading. (E ) Nicotine stimulates fibronectin protein expression in a time-dependent fashion. Cellular protein (5 mg) was isolated from H460 cells treated with 0.1 mM nicotine for the indicated period of time followed by Western blot analysis for fibronectin protein using an anti-fibronectin antibody. Blots were also incubated with an anti-GAPDH antibody to control for gel loading. Right panels: densitometric analysis of Western blots for fibronectin protein. Results are expressed as the optical density of fibronectin and normalized to GAPDH levels. (F ) Nicotine increases the secretion of fibronectin protein into medium in a time-dependent fashion. Cellular protein (30 mg) was harvested from the conditioned medium of H460 cells treated with 10 24 M nicotine for the indicated period of time, followed by Western blot analysis for fibronectin using an antibody against cellular fibronectin. Right panel: desitometric analysis of Western blots for fibronectin protein normalized with total medium protein levels. Results are expressed as the optical density of fibronectin. *Significant difference from control untreated cells (P , 0.05).
pathways. Western blot analysis revealed that nicotine stimulated the phosphorylation of ERK1/2 and mTOR in a time-dependent manner, with peak expressions observed at 24 hours ( Figures 5A  and 5C ); longer exposure times to nicotine had no further effect. Nicotine also increased the phosphorylation of Akt in a timedependent fashion, with maximal expression at 2 hours ( Figure  5B ). As depicted in Figure 5D , the ERK inhibitor PD98059 (25 mM) blocked the expression of fibronectin induced by nicotine, whereas PD98059 alone had no effect. Also, nicotine-induced fibronectin expression was abrogated in the presence of the PI3-K inhibitor LY294002 (25 mM) and the mTOR inhibitor rapamycin (10 nM) ( Figures 5E and 5F ). The findings above indicated that the stimulatory effects of nicotine on fibronectin were associated with the activation of ERK and PI3-K/mTOR signaling pathways. In contrast, the inhibitor of PKC, Calphostin C (0.5 mM), and of PKA, H-89 (10 mM), had no effect on nicotine-induced fibronectin expression ( Figures 5G and 5H ).
DISCUSSION
Lung cancer is the leading cause of cancer death throughout the world, causing 1.2 million deaths annually (19) . The development of lung cancer, especially NSCLC, is strongly associated with smoking in 85 to 90% of cases (20) . Nicotine, an important component of cigarette smoke and originally thought only to be responsible for tobacco addiction, is now recognized for contributing to tobacco-related carcinogenesis by regulating two critical processes: tumor cell growth and apoptosis (21) . Previous studies demonstrated that nicotine stimulated the proliferation of both NSCLC and SCLC cells (3, 22) . The exposure time and dose of nicotine needed to induce NSCLS varied with different reports. Similar to the report of Tsurutani and coworkers (2), we found that nicotine induced the proliferation of NSCLC cells and that this effect was most noticeable at 5 days. However, this was different from the report of Dasgupta and colleagues (3), which showed significant proliferation of NSCLC cells at 18 hours (no other time points were shown). In that particular study, the growth-promoting effect of nicotine was most likely due to the fact that the cells were stimulated after a 48-hour period of serum starvation. In our study, conducted in the presence of serum, the most robust and consistent effect (more than 50% increase over control) was seen with nicotine concentrations of 10 24 M, which was similar to the results of Quik and coworkers (23) and somewhat higher than that found H460 cells were cultured with anti-human a5b1 or a2b1 integrin antibodies (25 mg/ml, each) for 2 hours before exposure of the cells to nicotine (10 24 M) for up to 5 days. Afterward, luminescence was quantified using the Cell Titer-Glo Luminescent Cell Viability Assay Kit according to the manufacturer's instructions (Promega). (B) GRGDdSP peptide inhibits cell growth induced by nicotine. H460 cells were cultured with GRGDdSP or GRGESP peptides (2.5 mM, each) for 2 hour before exposure of the cells to nicotine (10 24 M) for up to 5 days. Afterward, the luminescence was quantified using Cell Titer-Glo Luminescent Cell Viability Assay Kit. (C ) a5 shRNA reduces a5 protein expression. Cellular protein (15 mg) was isolated from H460 cells, which were transfected by electroporation with a5 shRNA or control shRNA and incubated for 48 hours, and then subject to Western blot analysis for the integrin a5. Blots were also incubated with an anti-GAPDH antibody for normalization purposes. (D) a5 shRNA inhibits cell growth induced by nicotine. H460 cells transfected with a5 shRNA or control shRNA by electroporation were added to 48-well tissue culture plates and incubated with 10 24 M nicotine for 5 days, then subjected to cell viability analysis. All data are depicted as mean 6 SD. *Significant difference from control condition (P , 0.05); **significance of combination treatment as compared with nicotine alone. C, control; N, nicotine; RGD, GRGDdSP peptide; RGE, GRGESP peptide.
by others (24) . Although nicotine has been shown to inhibit lung cancer cell apoptosis caused by diverse stimuli including chemotherapeutic drugs, serum deprivation, and tumor necrosis factor (25), we found that exposure to nicotine had no effect on apoptosis of NSCLC cells as determined by caspase 3/7 assay, which is consistent with the results of Tsurutani and colleagues (2) . The results suggested that increased proliferation (and not decreased apoptosis) was responsible for the mitogenic effects of nicotine.
The most significant finding of this report is that fibronectin appears to mediate, at least in part, the mitogenic effects of nicotine. This is important when considered together with Results are expressed as the optical density of fibronectin and normalized to GAPDH levels. (E ) The effect of a-bungarotoxin on nicotine-induced fibronectin mRNA levels. Total RNA was isolated from H460 cells cultured for 1 hour in the presence or absence of a-bungarotoxin (1 mM) before exposure to nicotine (0.1 mM) for an additional 48 hours, followed by RT-PCR for fibronectin mRNA. Right panel: densitometric analysis of RT-PCR for fibronectin mRNA. Results are expressed as the optical density of fibronectin and normalized to GAPDH levels. *Significant difference from control untreated cells (P , 0.05). **Significance of combined treatments compared with nicotine treatment alone (P , 0.05). BGT, bungarotoxin.
information indicating that tumor growth and invasion are not only the result of malignant transformation, but also depend on environmental influences from their surrounding stroma, local growth factors, and systemic hormones. In particular, the composition of the extracellular matrix is believed to affect malignant behavior in vivo. Fibronectin, a matrix glycoprotein, is believed to play important roles in lung development, injury, and repair (26) . It can modulate many cellular functions such as cell adhesion, migration, chemotaxis, proliferation, differentiation, and apoptosis (27) . Fibronectin has also been implicated in Figure 5 . The effect of nicotine on the phosphorylation of ERK, Akt, and mTOR, and the role of ERK, PI3-K/mTOR, and PKC pathways in the induction of fibronectin by nicotine. (A) Nicotine stimulates phosphorylation of ERK1/2 in a time-dependent fashion. Cellular protein (20 mg) was isolated from H460 cells treated with nicotine (0.1 mM) for the indicated period of time followed by Western blot analysis for phosphorylated-ERK1/2 (p-ERK1/ 2) and total ERK1/2 determinations. Blots were also incubated with an anti-GAPDH antibody to control for gel loading. carcinogenesis (28, 29) , and a linkage between fibronectin and lung carcinoma has been suggested before, but the mechanisms responsible for this have not been fully elucidated. Fibronectin expression is increased in lung carcinomas, especially in NSCLC (5, 30) . Interestingly, the adhesion of lung carcinoma cells to fibronectin enhances tumorigenicity and confers resistance to apoptosis induced by standard chemotherapeutic agents (6) . Studies in other cell systems have implicated decreased apoptosis and increased DNA synthesis as mechanisms for the mitogenic effect of fibronectin (31) . Studies from our group have shown that fibronectin stimulates human lung carcinoma cell growth (9) (10) (11) . These studies show that fibronectin stimulates NSCLC cell proliferation through the activation of the integrin a5b1, induction of COX-2, inhibition of tumor suppressor genes, and stimulation of the Akt/mTOR pathway. Of note, type I collagen and fibrin do not exert these effects, and reagents against integrins other than a5b1 do not block the mitogenic effects of fibronectin (9) (10) (11) . These observations are consistent with other reports showing a positive correlation between expression of fibronectin and aggressive lung carcinoma behavior (32, 33) . These studies suggest that excessive expression of fibronectin might create an extracellular environment that stimulates lung carcinoma proliferation. However, they failed to unveil the relative contribution of tumor-derived fibronectin.
We therefore investigated the role of tumor-derived fibronectin in this process. We found that nicotine stimulates the expression of fibronectin. In order to confirm the role of fibronectin in nicotine-induced tumor cell proliferation, we inhibited cell recognition of fibronectin with agents that block fibronectin binding to its integrin receptor a5b1. This heterodimeric receptor belongs to the integrin family of transmembrane receptors involved in cell-matrix interactions, cell-cell adhesion, differentiation, wound healing, and altered invasive properties of tumor cells (34) . Data from our laboratory and that of others suggest that fibronectin, via its interaction with a5b1 in tumor cells, affects lung carcinoma cell functions (9) (10) (11) 35) . Here, we show that the mitogenic effect of nicotine was blocked by three interventions. First, we found that nicotine-induced proliferation was inhibited by antibodies against a5b1. The process was also blocked by the GRGDdSP peptide which competes with the ligand for a5b1 binding, whereas a2b1 antibodies and the control GRGESP peptide had no effect. Furthermore, silencing a5 by a5 shRNA also inhibited cell growth induced by nicotine. These findings suggested a novel role for the integrin a5b1 in mediating the mitogenic effect of nicotine, and support the hypothesis that nicotine stimulates lung carcinoma cell growth, at least in part, through fibronectin-a5b1 interactions. Although it is conceivable that a5b1 might be activated by molecules other than fibronectin, our published and unpublished collective data suggest that fibronectin is largely responsible for this effect.
One intriguing observation made was that maximal stimulation of NSCLC proliferation occurred with a nicotine dose of 10 24 M, which was observed at 5 days after stimulation, whereas maximal stimulation of intracellular fibronectin expression in lung cancer cells occurred at a dose of 10 27 M 48 hours after nicotine stimulation with decreased expression at higher doses. However, fibronectin secreted into medium increased significantly at 4 and 5 days of nicotine treatment coinciding with the period of maximal tumor cell proliferation, thus strongly implicating fibronectin in this process.
We next focused on the mechanisms responsible for the nicotine-induced fibronectin response in NSCLC cells. Studies available to date in neuronal cells show that nicotine acts mainly via nAChRs, which are a family of multimeric acetylcholine triggered action channel proteins that form the predominant excitatory neurotransmitter receptors on muscles and nerves in the peripheral nervous system (36) . Once thought to be restricted to neuronal cells, nAChR subunit expression has been demonstrated in human lung epithelial cells and lung carcinoma cells (12) . The most abundant homomeric nAChR form in humans is the a7 nAChR, and it seems to mediate the effects of nicotine in the lung (37) . It has also been reported in lung carcinoma cells, and the growth of these cells can be inhibited by a-bungarotoxin, a specific antagonist of a7 nAChRs (38) . These observations indicated that a7 nAChR may play an important role in the growth of lung cancers. Moreover, our previous study suggested that nicotine induces lung fibroblasts to produce fibronectin by stimulating a7 nAChR-dependent signals that regulate the transcription of the fibronectin gene. Altogether, these observations prompted us to examine the expression and function of a7 nAChR in nicotine-induced fibronectin expression in NSCLC. We found that nicotine dramatically increased a7 nAChR expression. This was consistent with one study showing that chronic exposure to nicotine in pregnant women may up-regulate the expression of a7 nAChR (39) . Of note, the up-regulation of fibronectin induced by nicotine was abolished by a-bungarotoxin, an inhibitor of a7 nAChRs. These results suggest that NSCLC cells express functional a7 nAChRs and that, by binding to these receptors, nicotine up-regulates fibronectin expression. We should highlight the fact that a7 nAChR receptor expression decreased when higher doses of nicotine (. 10 26 ) were used. This receptor down-regulation might explain the decrease in intracellular fibronectin content observed at these doses. However, one would have to invoke the elicitation of other signaling pathways involved in NSCLC proliferation at these higher doses of (and prolonged exposure to) nicotine to explain the observed kinetics of NSCLC proliferation. This requires further exploration.
The intracellular pathways mediating the effect of nicotine on fibronectin expression in NSCLC have not been elucidated. The PI3K/Akt pathway is a critical pathway in cancer because it contributes to tumorigenesis, tumor growth, and therapeutic resistance (40) . Akt serves at a nodal point in this pathway and is probably important for the development and maintenance of lung cancer (2) . The mTOR serine/threonine kinases play an important role in the translational control of gene expression during cell growth and the overall rate of protein synthesis in response to nutrients and other environmental factors (41, 42) . mTOR is also a key intermediary in multiple mitogenic signaling pathways and plays a central role in modulating cellular proliferation and angiogenesis in normal tissues and neoplastic processes (43) . The primary pathway by which growth factors and cytokines activate mTOR and its downstream targets seems to be the PI3K/Akt pathway. Studies suggest that Akt activation is an early event that is related to exposure to tobacco components (44) , and nicotinic activation of Akt increased phosphorylation of multiple downstream substrates of Akt in a time-dependent manner, including mTOR. Moreover, nicotine was found to stimulate Akt-dependent proliferation in lung cancer cells (2) . Studies also demonstrated the role of ERK in mediating nicotine-induced proliferation effects (45, 46) . Consistent with these, we showed that nicotine increased phosphorylation of ERK, Akt, and mTOR, and that blockade of these pathways abrogated the effect of nicotine on fibronectin expression, strongly suggesting a role for these signal pathways in this processes. These results suggest that targeting these signaling pathways might aid in the development of novel agents with therapeutic potential for the prevention and treatment of human lung carcinoma related to tobacco exposure. Rapamycin and several of its analogs, with more favorable pharmaceutical properties, have shown impressive growth-inhibitory effects against a broad range of human cancers in both preclinical and early clinical evaluations, including NSCLC (42) . PKC and PKA signaling pathways have also been shown to be activated by nicotine in human lung cancer and other cell systems (47, 48) . However, in this study, we found that the inhibitor of PKC, Calphostin C, and of PKA, H-89, had no effect on nicotine-induced fibronectin expression. The doses used for Calphostin C and H-89 were based on previous studies by this group and others (11, 49) .
In summary, our study suggests that nicotine, by binding to a7 nAChRs, stimulates NSCLC growth through induction of fibronectin gene expression that was dependent on activation of ERK and PI3-K/mTOR signaling pathways ( Figure 6 ). This work adds to the observations of others that highlight different signaling pathways by which nicotine stimulates NSCLC proliferation. It also unveils a novel role for fibronectin and matrix-binding integrins in tobacco-related lung carcinoma cell progression, and suggests potential new targets for the development of adjuvant therapies in tobacco-related tumors. 
